Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions.

NCT07410143 is registered in ClinicalTrials.gov with EveryONE Medicines Inc. as lead sponsor.

NCT NCT07410143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07410143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions.
Lead sponsor
EveryONE Medicines Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 13, 2026
Completion date
October 31, 2026
Enrollment
1 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric sdlt cns disorders